Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

EXP-16-01 ClinicalTrials.gov: NCT03023319

Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors N. Abdel Karim Ihab Azab Non-Small Cell Lung Cancer I

GCC-20-009 ClinicalTrials.gov: NCT04173325

Phase 1 Safety and Feasibility study of Nivolumab in combination with Irinotecan in relapsed or refractory Small Cell Lung Cancer N. Abdel Karim Ihab Azab Small Cell Lung Cancer I

IST 65 ClinicalTrials.gov: NCT04173338

Phase I study of cabozantinib in combination with pemetrexed in advanced non-squamous non-small cell lung cancer (NSCLC), urothelial cancer and advanced solid tumors  N. Abdel Karim Ihab Azab Non-Small Cell Lung Cancer I

NRG-LU004 ClinicalTrials.gov: NCT03801902

Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)  N. Abdel Karim Sandra Duncan Non-Small Cell Lung Cancer I

TESARO 4020-01-001 ClinicalTrials.gov: NCT02817633

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors N. Abdel Karim Sandra Duncan Non-Small Cell Lung Cancer I

NKTR 16-214-05 ClinicalTrials.gov: NCT03138889

A Phase 1/2a, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Anti-PD-1 (Pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors N. Abdel Karim Sandra Duncan Non-Small Cell Lung Cancer I/IIa

NRG-LU002 ClinicalTrials.gov:  NCT03137771

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial N. Abdel Karim Sandra Duncan Non-Small Cell Lung Cancer II/III

A081105 (ALCHEMIST)  ClinicalTrials.gov:   NCT02193282

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) S. Ghamande Inquiries Small Cell Lung Cancer III

CA209-73L ClinicalTrials.gov: NCT04026412

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) N. Abdel Karim Sandra Duncan Non-Small Cell Lung Cancer III

CA209-77T ClinicalTrials.gov: NCT04025879

A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer N. Abdel Karim Sandra Duncan Non-Small Cell Lung Cancer III

E4512 (ALCHEMIST)  ClinicalTrials,gov:   NCT02201992

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein S. Ghamande Inquiries Small Cell Lung Cancer III

EA5142  ClinicalTrials.gov:   NCT02595944

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer S. Ghamande Inquiries Small Cell Lung Cancer III